Already a Bloomberg.com user?
Sign in with the same account.
Oct. 24 (Bloomberg) -- U.S. regulators said they’re concerned about a study on AtriCure Inc.’s alternative during open-heart surgery to treat an irregular heartbeat.
The device system from the West Chester, Ohio-based company to destroy heart tissue during surgery is set to be considered by a Food and Drug Administration advisory panel on Oct. 26.
To contact the reporter on this story: Anna Edney in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Adriel Bettelheim at email@example.com